We are live on ! Find out more

898 hedge funds and large institutions have $10.8B invested in GSK in 2023 Q4 according to their latest regulatory filings, with 129 funds opening new positions, 270 increasing their positions, 344 reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $227M | Put options by funds: $104M

105% more first-time investments, than exits

New positions opened: 129 | Existing positions closed: 63

26% more capital inflows, than outflows

Capital inflows: $967M | Capital outflows: $767M

8% more funds holding in top 10

Funds holding in top 10: 12 → 13 (+1)

6% more funds holding

Funds holding: 847 → 898 (+51)

0.19% more ownership

Funds ownership: 13.96% → 14.15% (+0.19%)

22% less repeat investments, than reductions

Existing positions increased: 270 | Existing positions reduced: 344

Holders
898
Holders Change
+51
Holders Change %
+6.02%
% of All Funds
13.06%
Holding in Top 10
13
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+8.33%
% of All Funds
0.19%
New
129
Increased
270
Reduced
344
Closed
63
Calls
$227M
Puts
$104M
Net Calls
+$123M
Net Calls Change
-$164M

GSK Hedge Fund Activity: Q4 2023 in Review

898 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2023, worth a combined $10.8B — up 4.2% from $10.4B a quarter earlier.

Buyers outnumbered sellers: 129 funds opened new GSK positions and 63 closed out — a net gain of 66 holders — while 270 added to existing stakes and 344 trimmed.

The largest buyer was Holocene Advisors, adding an estimated $115M. The largest seller was Deutsche Bank, cutting an estimated $159M.

  • 898 institutional investors held GSK (GSK) as of Q4 2023, up from 847 in Q3 2023.
  • Funds reported $10.8B of GSK stock for Q4 2023, up 4.2% quarter-over-quarter.
  • 129 funds opened new GSK positions in Q4 2023 and 63 closed out, a net change of +66 holders.
  • The largest GSK buyer in Q4 2023 was Holocene Advisors, an estimated $115M added.
  • The largest GSK seller in Q4 2023 was Deutsche Bank, an estimated $159M sold.

Based on aggregated 13F filings for Q4 2023.